Directorio

We are doing this study to try and find a way to detect breast cancer earlier or before it recurs.

We are doing this study to evaluate the safety and effectiveness of an experimental procedure using new technology called Exablate Model 4000 Type 2.0/2.1 for adults with glioblastoma brain tumors. We want to know what effects it has (good and bad) on biomarkers (an indicator of a condition or disease in the body) released into the bloodstream.

We are doing this study to find out if an experimental drug called zifibancimig (the study drug) is a safe and effective option for people with neovascular age-related macular degeneration (nAMD). We want to see how well it works in comparison to ranibizumab, which is an FDA-approved drug for the treatment of nAMD. Both the study drug and approved drug that are used in this study are given as eye implants.

We are doing this study to determine if long-term treatment with camizestrant after surgery is a safe and effective option for treating patients with early-stage ER+/HER2- breast cancer. We want to compare the outcomes of using camizestrant to current standard of care treatments (endocrine therapy).

We are doing this study to compare different approaches aimed at preventing strokes for people who have already had a stroke. We want to know what combination of drugs seems to have the best outcomes when it comes to stroke prevention.

We are doing this study to find out if an experimental drug called eplontersen (the study drug) is safe and helpful for people with cardiac amyloidosis. We are enrolling people who previously participated in a clinical trial for this drug called the CardioTTRansform study (ION-682884-CS2).

We are doing this study to see how different things, like medical and treatment history, affect outcomes in people with cardiac amyloidosis.

We are doing this study to find the safest and most effective dose of an experimental drug called Cilta-cel (the study drug) in patients with multiple myeloma (MM).